Last reviewed · How we verify
Pharmacotherapy for opioid use disorder
Pharmacotherapy for opioid use disorder is a Small molecule drug developed by Boston Medical Center. It is currently FDA-approved. Also known as: Naltrexone.
Boston Medical Center's pharmacotherapy for opioid use disorder is currently marketed, positioning it as an established treatment option in this critical therapeutic area. A key strength is the protection of its core composition patent, which is set to expire in 2028, providing a significant period of market exclusivity. The primary risk lies in the competitive landscape, where the drug faces challenges from other marketed therapies for opioid use disorder.
At a glance
| Generic name | Pharmacotherapy for opioid use disorder |
|---|---|
| Also known as | Naltrexone |
| Sponsor | Boston Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Sustained-release Dexamphetamine in Patients With Moderate to Severe Cocaine Use Disorder (PHASE2)
- Cannabidiol in Opioid Use Disorder and Chronic Pain (EARLY_PHASE1)
- High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer (PHASE3)
- IMPOWR-ME Project 1: Trial of Yoga and Physical Therapy Onsite at Opioid Treatment Programs (NA)
- Adaptive Interventions for Emergency Department Patients With Opioid Use Disorder (NA)
- The Whole Health Study: Collaborative Care for OUD and Mental Health Conditions (NA)
- A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder (PHASE4)
- Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pharmacotherapy for opioid use disorder CI brief — competitive landscape report
- Pharmacotherapy for opioid use disorder updates RSS · CI watch RSS
- Boston Medical Center portfolio CI
Frequently asked questions about Pharmacotherapy for opioid use disorder
What is Pharmacotherapy for opioid use disorder?
Who makes Pharmacotherapy for opioid use disorder?
Is Pharmacotherapy for opioid use disorder also known as anything else?
What development phase is Pharmacotherapy for opioid use disorder in?
Related
- Manufacturer: Boston Medical Center — full pipeline
- Also known as: Naltrexone
- Compare: Pharmacotherapy for opioid use disorder vs similar drugs
- Pricing: Pharmacotherapy for opioid use disorder cost, discount & access